SEPOY.net
No Result
View All Result
Friday, June 13, 2025
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

Study provides better understanding of how therapeutic resistance develops in lung cancer

Nicholas by Nicholas
July 1, 2022
in Health
0

New Cleveland Clinic research has uncovered key information about cellular interaction between tumor cells and normal tissue, providing better understanding of how therapeutic resistance develops.

READ ALSO

UK study finds small proportion of early Alzheimer’s patients suitable for latest treatments

Kennedy’s HHS sent Congress ‘junk science’ to defend vaccine changes, experts say

In the study of drug resistance, researchers often try to understand the fitness of cells that have specific mutations in the presence of a drug in a laboratory setting. But the reality is more complex, because tumor cells don’t exist in a vacuum; instead, they co-exist in a complex, heterogeneous mixture of other tumor cells and normal tissues -; an interacting ecology.”


Jacob Scott, M.D., D.Phil., radiation oncologist and head of Cleveland Clinic’s Theory Division in the Lerner Research Institute Department of Translational Hematology and Oncology Research

With approximately 90% of cancer deaths attributed to treatment-resistant disease, these cellular interactions, also known as “evolutionary games,” have high stakes.

In their latest study published DATE in Science Advances, Dr. Scott and his collaborators used an assay they previously developed to directly measure those interactions in a simplified tumor environment consisting of drug-resistant non-small cell lung cancer cells and drug-sensitive precursor (ancestor) cells.

Cells resistant to the metastatic non-small cell lung cancer treatment gefitinib were derived from existing lung cancer cells by continual treatment with gefitinib over six months, and grown in an in vitro co-culture experiment with their sensitive ancestors. Cellular growth dynamics were assessed with and without gefitinib.

“We cultured the two groups of cells together in different starting fractions and we measured how their growth changed depending on how much of each group was mixed together,” explained Jeff Maltas, Ph.D., a postdoctoral researcher at Cleveland Clinic and co-lead author on the study.

The researchers found that the fitness of the resistant type of cell changes drastically depending on the composition of the mixture. Experiments revealed that the resistant population was outcompeted by the ancestral line at all studied population frequencies in the absence of therapy, pointing to complete competitive exclusion of the resistant population and a cost of resistance.​ When gefitinib was added, there was a complete reversal of this effect, and the resistant clone was able to outcompete the sensitive ancestor.

This changing growth dynamics between treatment-resistant and treatment-sensitive cells could not be detected by standard assays available to date and suggests a novel mechanism by which resistant cells persist in the absence of treatment.

“This paper highlights the need to understand and directly measure those ecological interactions that come from being around other cell types,” Dr. Scott said. “That’s something we’re doing here that’s fundamentally different.”

Dr. Scott notes that although these latest findings cannot be directly extrapolated to clinical scenarios, they do raise important questions with potentially significant implications on clinical research and trial design. In broader terms, could patients benefit from taking a break from medication to allow the maintenance of a critical treatment-sensitive population of tumor cells? And, could treatment regimens consisting of on-treatment and off-treatment periods allow for better control of cancer cell growth and, in the long term, prolong the lives of patients?

“One of the most exciting parts of this paper is the opportunity for clinical advances that it highlights,” Dr. Scott said. The design and testing of dynamic treatment regimens that could keep cancer cells “in check” over the long term may be the next translational application of these important findings.

Cleveland Clinic’s Theory Division conducts cancer research to develop and make available novel diagnostic tools, targeted therapies and clinical trials for direct use in patient care.

Source:

Journal reference:

Farrokhian, N., et al. (2022) Measuring competitive exclusion in non-small cell lung cancer. Science Advances. doi.org/10.1126/sciadv.abm7212.

Tags: CancerCellGefitinibHematologyHospitalLaboratoryLung CancerNon-Small Cell Lung CancerOncologyResearchSmall Cell Lung CancerTumor

Related Posts

UK study finds small proportion of early Alzheimer’s patients suitable for latest treatments
Health

UK study finds small proportion of early Alzheimer’s patients suitable for latest treatments

June 13, 2025
Kennedy’s HHS sent Congress ‘junk science’ to defend vaccine changes, experts say
Health

Kennedy’s HHS sent Congress ‘junk science’ to defend vaccine changes, experts say

June 13, 2025
Prenatal exposure to forever chemicals linked to higher teen blood pressure
Health

Prenatal exposure to forever chemicals linked to higher teen blood pressure

June 13, 2025
Meal and sleep timing play key roles in diabetes prevention
Health

Meal and sleep timing play key roles in diabetes prevention

June 13, 2025
Higher trust leads to greater happiness and life satisfaction
Health

Higher trust leads to greater happiness and life satisfaction

June 12, 2025
Updated EU CAR-T Handbook offers insights into latest developments in CAR-T cell therapies
Health

Updated EU CAR-T Handbook offers insights into latest developments in CAR-T cell therapies

June 12, 2025
Next Post

‘The Ordinaries’ Director Sophie Linnenbaum on ‘Mechanisms of Exclusion’

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: hello@sepoy.net

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • Top-Ranked A real income Gambling enterprise Sites For us Participants
  • Baixela Casino Casino Hit The Gold Brasil Cassinos móveis afinar Brasil 2025 Central do Ciência
  • Gamble Black-jack On line the real deal Money United states of america 2025: Top ten Gambling enterprises

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net